Royalty Pharma plc Class A

1. 01

   1.9% below its 52-week high

   Closed at $66.40 on 3 Nov 2026: 1.9% below the 52-week high of $67.71 (30 Oct 2026) and 84.3% above the low of $36.03 (5 Nov 2025).

   Daily price bars, split-adjusted · as of 3 Nov 2026

2. 02

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +17.2% (SPY −2.6%, XLV +9.9%). 3 months: +15.5% (SPY −2.2%, XLV +13.5%). 1 year: +78.0% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: RPRX, SPY and XLV · as of 3 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 3 Nov 2026 close of $66.40 was 9.8% above its 50-day average ($60.48) and 24.1% above its 200-day average ($53.49). It has closed above the 200-day for 456 sessions, since 10 Jan 2025. The 50-day average crossed above the 200-day on 4 Feb 2025, 439 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

4. 04

   Next ex-dividend date: 13 Nov 2026

   $0.235 a share, payable 10 Dec 2026; unchanged from the previous payment (ex-date 14 Aug 2026).

   Corporate actions record · as of 4 Nov 2026

5. 05

   RSI(14) at 71.4, 70 or above

   The 14-session relative strength index closed at 71.4 on 3 Nov 2026, its 9th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.

   Daily closes, split-adjusted; Wilder's 14-session RSI · as of 3 Nov 2026

At the 3 Nov 2026 close